Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1989 Mar;83(3):1073–1077. doi: 10.1172/JCI113950

Relationship between whole plasma calcitonin levels, calcitonin secretory capacity, and plasma levels of estrone in healthy women and postmenopausal osteoporotics.

J Y Reginster 1, R Deroisy 1, A Albert 1, D Denis 1, M P Lecart 1, J Collette 1, P Franchimont 1
PMCID: PMC303786  PMID: 2921317

Abstract

The exact role of calcitonin (CT) in the pathogenesis of postmenopausal osteoporosis remains unknown. Whole plasma calcitonin (iCT) basal levels, metabolic clearance rate (MCR), and production rate (PR) of CT were measured in 9 premenopausal and 16 postmenopausal women, including 11 osteoporotics (OP). Basal iCT levels were statistically lower in postmenopausal women than in the premenopausal group (P less than 0.01) and strongly correlated (r = 0.72; P less than 0.001) with estrone circulating levels (E1). MCR were similar in all groups. PR were similar in eugonadal women between 22 (mean +/- SD = 30.9 +/- 9.9 micrograms/d) and 37 yr (mean +/- SD = 25.5 +/- 11.1 micrograms/d) premenopausal women. In healthy postmenopausal women PR were reduced, but not significantly (mean +/- SD = 19.5 +/- 6.95 micrograms/d), whereas osteoporotic patients presented a highly significant reduction of CT PR (mean +/- SD = 9.8 +/- 4 micrograms/d) (P less than 0.01). Because there is a strong relationship between E1 and PR (r = 0.64; P less than 0.001), CT secretory capacity appears to be modulated by estrogen circulating levels. This modulation leads to a menopause-related decrease in iCT. In osteoporotics, an independent impairment of CT production drastically lowers PR and basal iCT levels. CT might be one of the determining factors in the pathogenesis of postmenopausal osteoporosis.

Full text

PDF
1075

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bijvoet O. L., van der Sluys Veer J., Jansen A. P. Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia. Lancet. 1968 Apr 27;1(7548):876–881. doi: 10.1016/s0140-6736(68)90236-5. [DOI] [PubMed] [Google Scholar]
  2. Chesnut C. H., 3rd, Baylink D. J., Sisom K., Nelp W. B., Roos B. A. Basal plasma immunoreactive calcitonin in postmenopausal osteoporosis. Metabolism. 1980 Jun;29(6):559–562. doi: 10.1016/0026-0495(80)90082-7. [DOI] [PubMed] [Google Scholar]
  3. Cook C. L., Rao C. V., Yussman M. A. Plasma gonadotropin and sex steroid hormone levels during early, midfollicular, and midluteal phases of women with luteal phase defects. Fertil Steril. 1983 Jul;40(1):45–48. doi: 10.1016/s0015-0282(16)47175-x. [DOI] [PubMed] [Google Scholar]
  4. Deftos L. J., Roos B. A., Bronzert D., Parthemore J. G. Immunochemical heterogeneity of calcitonin in plasma. J Clin Endocrinol Metab. 1975 Mar;40(3):409–412. doi: 10.1210/jcem-40-3-409. [DOI] [PubMed] [Google Scholar]
  5. Deftos L. J., Weisman M. H., Williams G. W., Karpf D. B., Frumar A. M., Davidson B. J., Parthemore J. G., Judd H. L. Influence of age and sex on plasma calcitonin in human beings. N Engl J Med. 1980 Jun 12;302(24):1351–1353. doi: 10.1056/NEJM198006123022407. [DOI] [PubMed] [Google Scholar]
  6. Forney J. P., Milewich L., Chen G. T., Garlock J. L., Schwarz B. E., Edman C. D., MacDonald P. C. Aromatization of androstenedione to estrone by human adipose tissue in vitro. Correlation with adipose tissue mass, age, and endometrial neoplasia. J Clin Endocrinol Metab. 1981 Jul;53(1):192–199. doi: 10.1210/jcem-53-1-192. [DOI] [PubMed] [Google Scholar]
  7. Friedman J., Raisz L. G. Thyrocalcitonin: inhibitor of bone resorption in tissue culture. Science. 1965 Dec 10;150(3702):1465–1467. doi: 10.1126/science.150.3702.1465. [DOI] [PubMed] [Google Scholar]
  8. Heath H., 3rd, Sizemore G. W. Plasma calcitonin in normal man. Differences between men and women. J Clin Invest. 1977 Nov;60(5):1135–1140. doi: 10.1172/JCI108865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Heynen G., Franchimont P. Human calcitonin radioimmunoassay in normal and pathological conditions. Eur J Clin Invest. 1974 Jun;4(3):213–222. doi: 10.1111/j.1365-2362.1974.tb00395.x. [DOI] [PubMed] [Google Scholar]
  10. Hillyard C. J., Stevenson J. C., MacIntyre I. Relative deficiency of plasma-calcitonin in normal women. Lancet. 1978 May 6;1(8071):961–962. doi: 10.1016/s0140-6736(78)90249-0. [DOI] [PubMed] [Google Scholar]
  11. Kanis J. A., Heynen G., Cundy T., Cornet F., Paterson A., Russell R. G. An estimate of the endogenous secretion rate of calcitonin in man. Clin Sci (Lond) 1982 Aug;63(2):145–152. doi: 10.1042/cs0630145. [DOI] [PubMed] [Google Scholar]
  12. Loré F., Galli M., Franci B., Martorelli M. T. Calcitonin levels in normal subjects according to age and sex. Biomed Pharmacother. 1984;38(5):261–263. [PubMed] [Google Scholar]
  13. O'Riordan J. L., Aurbach G. D. Mode of action of thyrocalcitonin. Endocrinology. 1968 Feb;82(2):377–383. doi: 10.1210/endo-82-2-377. [DOI] [PubMed] [Google Scholar]
  14. Reginster J. Y., Denis D., Albert A., Deroisy R., Lecart M. P., Fontaine M. A., Lambelin P., Franchimont P. 1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet. 1987 Dec 26;2(8574):1481–1483. doi: 10.1016/s0140-6736(87)92619-5. [DOI] [PubMed] [Google Scholar]
  15. Rodbard D. Statistical estimation of the minimal detectable concentration ("sensitivity") for radioligand assays. Anal Biochem. 1978 Oct 1;90(1):1–12. doi: 10.1016/0003-2697(78)90002-7. [DOI] [PubMed] [Google Scholar]
  16. Singer F. R., Habener J. F. Multiple immunoreactive forms of calcitonin in human plasma. Biochem Biophys Res Commun. 1974 Nov 27;61(2):710–716. doi: 10.1016/0006-291x(74)91015-8. [DOI] [PubMed] [Google Scholar]
  17. Stevenson J. C., Abeyasekera G., Hillyard C. J., Phang K. G., MacIntyre I., Campbell S., Lane G., Townsend P. T., Young O., Whitehead M. I. Regulation of calcium-regulating hormones by exogenous sex steroids in early postmenopause. Eur J Clin Invest. 1983 Dec;13(6):481–487. doi: 10.1111/j.1365-2362.1983.tb00133.x. [DOI] [PubMed] [Google Scholar]
  18. Taggart H. M., Chesnut C. H., 3rd, Ivey J. L., Baylink D. J., Sisom K., Huber M. B., Roos B. A. Deficient calcitonin response to calcium stimulation in postmenopausal osteoporosis? Lancet. 1982 Feb 27;1(8270):475–478. doi: 10.1016/s0140-6736(82)91451-9. [DOI] [PubMed] [Google Scholar]
  19. Tiegs R. D., Body J. J., Barta J. M., Heath H., 3rd Secretion and metabolism of monomeric human calcitonin: effects of age, sex, and thyroid damage. J Bone Miner Res. 1986 Aug;1(4):339–349. doi: 10.1002/jbmr.5650010407. [DOI] [PubMed] [Google Scholar]
  20. Tiegs R. D., Body J. J., Wahner H. W., Barta J., Riggs B. L., Heath H., 3rd Calcitonin secretion in postmenopausal osteoporosis. N Engl J Med. 1985 Apr 25;312(17):1097–1100. doi: 10.1056/NEJM198504253121705. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES